Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline
26.1.2022 12:00:00 EET | Business Wire | Press release
Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium’s next-generation therapeutic candidates, engineered to deliver payloads within the tumor microenvironment.
“Prokarium is designing the perfect bacteria to be the next cancer immunotherapy, and we believe leveraging Salmonella’s unique biology will allow us to combine a powerful innate approach with a tailored adaptive response,” said Kristen Albright, PharmD, Chief Executive Officer of Prokarium. “This agreement will significantly expand our R&D capabilities and will further deepen our immunotherapy pipeline.”
This new multi-year agreement builds on work between Prokarium and London Biofoundry that was initiated in 2020 and will further expand Prokarium’s operations. The team from Imperial’s and SynbiCITE’s London Biofoundry specializes in the design, engineering and functional characterisation of synthetic DNA and organisms.
“Prokarium has uniquely positioned their Salmonella platform as an innovative immunotherapy approach for the treatment of solid tumors, and we are excited to support their efforts in pioneering the cancer treatment paradigm shift from synthetic chemistry to synthetic biology,” said Marko Storch, PhD, Head of Synthetic Biology and Automation. “At the London Biofoundry, we developed a cutting-edge SynBio stack and the expertise to collaborate with researchers and biotechs to advance their R&D. We are thrilled to leverage our leading research capabilities to support the development of Prokarium’s new class of medicines in oncology.”
About the London Biofoundry
The London Biofoundry provides a suite of state-of-the-art robotic equipment and expertise supporting automated end-to-end design, construction, and validation of large gene constructs and biological systems. For more information visit www.londonbiofoundry.org
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. For more information visit http://www.imperial.ac.uk/
About Prokarium
Prokarium is a biopharmaceutical company pioneering the field of microbial immunotherapy. Our pipeline is designed to unlock the next level of immuno-oncology by building on the most recent advances in cancer immunology. Prokarium’s lead program is focused on transforming the treatment paradigm in bladder cancer by orchestrating immune-driven, long-lasting antitumor effects. Prokarium is based in London, UK. For further information, visit https://www.prokarium.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005069/en/
Contact information
Contacts
For Prokarium
Kristen Albright
Chief Executive Officer
kristen.albright@prokarium.com
www.prokarium.com
For media
MacDougall Advisors
Matthew Corcoran
+1 781-235-3060
prokarium@macdougall.bio
www.macdougall.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New ABB and BCG Report Highlights Growing Role of Direct Current Technologies in Future Power Systems9.9.2026 12:42:00 EEST | Press release
ABB today published a new report, The Strategic Case for Hybrid AC/DC Power: Shaping the Transition to the Next Electrical Architecture, developed in collaboration with Boston Consulting Group (BCG). The report makes the case that direct current (DC) technology is moving from the periphery to the center of industrial, commercial, and digital infrastructure – and that the decisions made by business leaders and policymakers in the next two to three years will determine who shapes that transition and who inherits it. The future of power distribution is not an either-or choice between alternating current (AC) and direct current, but a hybrid system that combines the strengths of both technologies. While AC will remain the backbone of most transmission and regional distribution networks, DC is expected to play an increasingly important role within facilities where many major energy sources and loads already operate natively on direct current. The fastest-growing technologies, including sola
Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities9.9.2026 12:00:00 EEST | Press release
Chiesi Group ("Chiesi"), an international research-focused biopharmaceutical company and certified B Corp, today announced its financial results for the six months ended 30 June 2026 ("H1 2026"). Performance across therapeutic areas and regions Chiesi reported revenues of €1.89 billion, representing growth of +3.6% at constant exchange rates (CER) compared with H1 2025. These results do not include the impact of the recent acquisition of KalVista Pharmaceuticals. The Group's growth is supported by continued expansion of its global rare diseases area (+€45m; +9.9% @CER), and sustained performance in neonatology and specialty care therapeutic areas (+6.5% @CER). The respiratory health area remains broadly stable (-0.8% @CER) fueled by the strong growth in our inhaled triple therapy portfolio. Driven by the ongoing execution of its international growth strategy, Chiesi continued to expand its presence in key markets, with particularly strong momentum in the United States (+9.6% @CER), whi
Visa and World Bank Group Announce New Risk-Sharing Initiative to Expand Digital Payments and Financial Inclusion in Emerging Markets9.9.2026 12:00:00 EEST | Press release
Visa (NYSE: V), a global leader in digital payments, and the International Finance Corporation (IFC), a member of the World Bank Group focused on the private sector, are partnering on an innovative risk-sharing initiative designed to help expand financial inclusion by increasing access to digital financial services in emerging markets. Under the agreement, IFC will share credit settlement risk for Visa transactions associated with enrolled financial institutions, enabling these institutions to connect more underbanked consumers and small businesses to digital payments. The facility is expected to support approximately $200 million in risk sharing over five years, with an initial focus on 14 countries in Latin America and the Caribbean and reach approximately 50 financial institutions with below-investment grade ratings. Together, Visa and IFC aim to help financial institutions enable millions more people and small businesses to save, spend, borrow, grow, and participate more fully in t
Ant Group Open-Sources Ling-3.0-flash-Fin for Real-World Financial Workflows9.9.2026 11:36:00 EEST | Press release
Ant Group today announced the open-sourcing of Ling-3.0-flash-Fin at the 2026 Inclusion·Conference on the Bund. Grounded in actual business needs as an open model for real-world financial workflows, this release continues Ant Group's exploration of bringing AI into practical scenarios, focusing on delivering utility and high efficiency for complex tasks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908565055/en/ Solving Real-World Challenges Through Efficiency Financial work depends on trustworthy sources, consistent definitions, accurate calculations and auditable outputs. AI in this sector must go beyond simple question-and-answer interactions to navigate dynamic information, complex accounting standards, and stringent compliance requirements. Ling-3.0-flash-Fin was co-developed with leading financial institutions and industry experts to embed professional expertise directly into task definition, data systems, and eva
1NCE adds Data Benchmarking, AI Capabilities and ISO certification9.9.2026 11:00:00 EEST | Press release
1NCE announced a new upgrade of 1NCE Insights and the launch of 1NCE AI. Both expand 1NCE's foundational platform services, giving customers greater intelligence and control over connected device data. The new 1NCE Insights upgrade gives customers access to aggregated benchmark data from 30,000+ deployments. They can compare network usage patterns, battery performance, hardware choices and traffic optimization against real-world peers, enabling faster product development. 1NCE AI provides access to leading AI models through a unified API gateway, eliminating vendor fragmentation. The service is Germany-hosted and fully GDPR-compliant, with 1NCE's Token service enabling customers to manage and optimize AI token costs across all models. Data security is foundational. Customer-collected data belongs to the customer. 1NCE Insights uses only anonymized, aggregated network data. 1NCE's infrastructure is ISO/IEC 27001:2022 certified by TÜV Rheinland, valid through 2029. "Our platform gives cu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom